Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NLTX NASDAQ:OSMT NASDAQ:SLRN NASDAQ:TSVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNLTXNeoleukin Therapeutics$22.54+5.0%$18.68$2.03▼$14.36$211.83M1.1150,104 shs89,846 shsOSMTOsmotica Pharmaceuticals$1.16$0.98▼$4.95$69.47M2.34396,682 shs296,500 shsSLRNAcelyrin$2.27$2.27$1.85▼$7.25$229.17M1.071.28 million shsN/ATSVT2seventy bio$5.00$5.00$2.29▼$5.30$266.15M1.04643,143 shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNLTXNeoleukin Therapeutics-3.55%+5.87%+8.65%+99.35%-53.07%OSMTOsmotica Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SLRNAcelyrin0.00%0.00%0.00%+3.18%-67.85%TSVT2seventy bio0.00%0.00%0.00%+0.40%+1.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOSMTOsmotica PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/AN/AN/AN/ATSVT2seventy bioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNLTXNeoleukin Therapeutics 0.00N/AN/AN/AOSMTOsmotica Pharmaceuticals 0.00N/AN/AN/ASLRNAcelyrin 2.40Hold$9.60322.91% UpsideTSVT2seventy bio 2.00Hold$5.00N/ACurrent Analyst Ratings BreakdownLatest OSMT, TSVT, SLRN, and NLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/10/2025TSVT2seventy bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)4/24/2025TSVT2seventy bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/AOSMTOsmotica Pharmaceuticals$177.88M0.00N/A1.00$1.50 per share0.00SLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/ATSVT2seventy bio$48.37M5.50N/AN/A$5.04 per share0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/AOSMTOsmotica Pharmaceuticals-$79.59M-$1.59N/AN/AN/A-138.76%-81.23%-20.97%N/ASLRNAcelyrin-$381.64M-$2.69N/AN/AN/AN/A-44.12%-39.02%8/12/2025 (Estimated)TSVT2seventy bio-$217.57M-$0.10N/AN/AN/A-207.25%-53.65%-23.67%8/6/2025 (Estimated)Latest OSMT, TSVT, SLRN, and NLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025SLRNAcelyrin-$0.71N/AN/AN/AN/AN/A8/6/2025Q2 2025TSVT2seventy bio-$0.05N/AN/AN/A$15.45 millionN/A5/14/2025Q1 2025SLRNAcelyrin-$0.95-$0.55+$0.40-$0.55N/AN/A5/7/2025Q1 2025TSVT2seventy bio-$0.10$0.01+$0.11$0.01$13.96 million$22.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AOSMTOsmotica PharmaceuticalsN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/ATSVT2seventy bioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNLTXNeoleukin TherapeuticsN/A15.3315.33OSMTOsmotica PharmaceuticalsN/A0.430.42SLRNAcelyrinN/A7.157.15TSVT2seventy bioN/A4.954.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNLTXNeoleukin Therapeutics52.37%OSMTOsmotica Pharmaceuticals46.18%SLRNAcelyrin87.31%TSVT2seventy bio93.90%Insider OwnershipCompanyInsider OwnershipNLTXNeoleukin Therapeutics1.58%OSMTOsmotica Pharmaceuticals5.22%SLRNAcelyrin13.60%TSVT2seventy bio7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataOSMTOsmotica Pharmaceuticals30262.59 million59.32 millionNot OptionableSLRNAcelyrin135100.95 million86.68 millionOptionableTSVT2seventy bio44053.23 million47.87 millionOptionableOSMT, TSVT, SLRN, and NLTX HeadlinesRecent News About These Companies2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers SquibbMay 7, 2025 | businesswire.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTApril 16, 2025 | businesswire.com2seventy Bio reports Q4 EPS (37c) vs ($1.11) last yearMarch 27, 2025 | markets.businessinsider.com2seventy bio Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 25, 2025 | businesswire.comJessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) StockMarch 20, 2025 | insidertrades.com2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's WhyMarch 17, 2025 | zacks.com2seventy Bio price target lowered to $5 from $6 at Morgan StanleyMarch 14, 2025 | markets.businessinsider.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTMarch 14, 2025 | businesswire.com2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in StockMarch 14, 2025 | insidertrades.comBiotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMarch 13, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVTMarch 12, 2025 | prnewswire.comShareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public ShareholdersMarch 11, 2025 | businesswire.com2seventy bio accepts Bristol Myers’ takeover bidMarch 11, 2025 | thepharmaletter.comTBiotech Stock 2seventy bio, Inc. (Nasdaq: TSVT) Soars on Acquisition NewsMarch 11, 2025 | investorideas.comITSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to ShareholdersMarch 11, 2025 | tmcnet.com2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cashMarch 11, 2025 | markets.businessinsider.comTSVT Up on Acquisition Agreement With BMY for $286 MillionMarch 11, 2025 | zacks.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.March 11, 2025 | prnewswire.comBristol Myers buys out cell therapy partner 2seventy bioMarch 11, 2025 | endpts.comE2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers SquibbMarch 10, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOSMT, TSVT, SLRN, and NLTX Company DescriptionsNeoleukin Therapeutics NASDAQ:NLTX$22.54 +1.07 (+4.98%) As of 07/16/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Osmotica Pharmaceuticals NASDAQ:OSMTOsmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.Acelyrin NASDAQ:SLRNAcelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.2seventy bio NASDAQ:TSVT2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.